Cardiol Therapeutics Files 6-K Report
Ticker: CRDL · Form: 6-K · Filed: Apr 2, 2024 · CIK: 1702123
| Field | Detail |
|---|---|
| Company | Cardiol Therapeutics INC. (CRDL) |
| Form Type | 6-K |
| Filed Date | Apr 2, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, news-release
TL;DR
Cardiol Therapeutics filed a 6-K, likely with a news release attached. Keep an eye out for updates.
AI Summary
Cardiol Therapeutics Inc. filed a Form 6-K on April 2, 2024, to report information for the month of April 2024. The filing includes Exhibit 99.1, which is a news release dated April 2, 2024. The company is incorporated in Canada and its principal executive offices are located in Oakville, Ontario.
Why It Matters
This filing indicates that Cardiol Therapeutics Inc. is providing updated information to the SEC, which could include significant business developments or financial updates relevant to investors.
Risk Assessment
Risk Level: low — A Form 6-K is a routine filing for foreign private issuers to report information that is made public in their home country, typically not containing material new information on its own.
Key Numbers
- 001-40712 — SEC File Number (Identifies the company's filing history with the SEC)
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Filer of the 6-K report
- 0001062993-24-007668 (accession_number) — Unique identifier for the SEC filing
- April 2, 2024 (date) — Filing date and date of news release
- Oakville, Ontario, Canada (location) — Location of principal executive offices
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is filed by Cardiol Therapeutics Inc. to report information that it has made or will make public in Canada, as required for foreign private issuers.
What is included as an exhibit with this filing?
Exhibit 99.1, a news release dated April 2, 2024, is submitted with this Form 6-K.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on April 2, 2024.
Where are Cardiol Therapeutics Inc.'s principal executive offices located?
The company's principal executive offices are located at 602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5.
Does Cardiol Therapeutics Inc. file annual reports under Form 20-F or Form 40-F?
Cardiol Therapeutics Inc. indicates it files annual reports under Form 20-F.
Filing Stats: 215 words · 1 min read · ~1 pages · Grade level 12.8 · Accepted 2024-04-02 06:02:50
Filing Documents
- form6k.htm (6-K) — 5KB
- exhibit99-1.htm (EX-99.1) — 19KB
- exhibit99-1xu001.jpg (GRAPHIC) — 8KB
- 0001062993-24-007668.txt ( ) — 36KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: April 2, 2024 By: /s/ Chris Waddick Chris Waddick Title: Chief Financial Officer